Telomir Pharmaceuticals (TELO) Competitors $1.57 -0.05 (-3.09%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.58 +0.01 (+0.64%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. IPHA, MIST, FBRX, CRBP, ANRO, SAVA, GNLX, ELDN, IVVD, and ACTUShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Innate Pharma (IPHA), Milestone Pharmaceuticals (MIST), Forte Biosciences (FBRX), Corbus Pharmaceuticals (CRBP), Alto Neuroscience (ANRO), Cassava Sciences (SAVA), Genelux (GNLX), Eledon Pharmaceuticals (ELDN), Invivyd (IVVD), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors Innate Pharma Milestone Pharmaceuticals Forte Biosciences Corbus Pharmaceuticals Alto Neuroscience Cassava Sciences Genelux Eledon Pharmaceuticals Invivyd Actuate Therapeutics Innate Pharma (NASDAQ:IPHA) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Which has more volatility & risk, IPHA or TELO? Innate Pharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.6, meaning that its stock price is 160% less volatile than the S&P 500. Do analysts rate IPHA or TELO? Innate Pharma presently has a consensus target price of $6.50, suggesting a potential upside of 200.23%. Telomir Pharmaceuticals has a consensus target price of $15.00, suggesting a potential upside of 855.41%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than Innate Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Telomir Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has higher earnings & valuation, IPHA or TELO? Telomir Pharmaceuticals has lower revenue, but higher earnings than Innate Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$21.77M9.17-$53.53MN/AN/ATelomir PharmaceuticalsN/AN/A-$16.53M-$0.54-2.91 Do insiders and institutionals hold more shares of IPHA or TELO? 0.2% of Innate Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is IPHA or TELO more profitable? Innate Pharma's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Telomir Pharmaceuticals N/A -4,595.08%-1,750.91% Does the media favor IPHA or TELO? In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than Innate Pharma. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for Innate Pharma. Telomir Pharmaceuticals' average media sentiment score of 0.03 beat Innate Pharma's score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryInnate Pharma and Telomir Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.68M$2.97B$6.19B$10.55BDividend YieldN/A54.20%5.70%4.81%P/E Ratio-2.9122.9985.5427.13Price / SalesN/A765.78611.78133.04Price / CashN/A169.4137.1060.81Price / Book78.505.3212.236.52Net Income-$16.53M$33.06M$3.33B$276.93M7 Day Performance-4.85%2.29%1.17%1.93%1 Month Performance2.61%7.35%6.85%2.19%1 Year Performance-66.60%-5.13%58.93%34.62% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.8557 of 5 stars$1.57-3.1%$15.00+855.4%-66.6%$50.68MN/A-2.911Short Interest ↓Gap DownIPHAInnate Pharma2.0856 of 5 stars$1.96-0.8%$6.50+231.6%+9.3%$182.12M$21.77M0.00220MISTMilestone Pharmaceuticals2.1545 of 5 stars$2.08-1.9%$4.50+116.3%+30.2%$180.19M$1M-2.4830FBRXForte Biosciences2.7809 of 5 stars$14.23-1.4%$68.00+377.9%+157.6%$179.41MN/A-0.875News CoverageAnalyst DowngradeOptions VolumeCRBPCorbus Pharmaceuticals3.9477 of 5 stars$14.61+0.6%$45.43+210.9%+4.9%$177.95MN/A-3.0740ANROAlto Neuroscience1.9334 of 5 stars$5.96-8.9%$9.80+64.4%-57.8%$177.08MN/A-2.49N/ASAVACassava Sciences2.4851 of 5 stars$3.42-4.2%$2.00-41.5%-85.2%$172.46MN/A-1.3430GNLXGenelux0.8306 of 5 stars$4.71+3.7%$20.33+331.7%+108.0%$171.49M$10K-5.4810ELDNEledon Pharmaceuticals1.8091 of 5 stars$2.73-4.5%$10.00+266.3%+15.8%$171.26MN/A-2.3310News CoverageGap UpIVVDInvivyd3.8523 of 5 stars$1.63+14.8%$5.14+215.2%+80.0%$170.60M$25.38M-1.77100Analyst DowngradeHigh Trading VolumeACTUActuate Therapeutics1.444 of 5 stars$7.04+0.3%$20.33+188.8%+3.0%$163.17MN/A0.0010 Related Companies and Tools Related Companies Innate Pharma Alternatives Milestone Pharmaceuticals Alternatives Forte Biosciences Alternatives Corbus Pharmaceuticals Alternatives Alto Neuroscience Alternatives Cassava Sciences Alternatives Genelux Alternatives Eledon Pharmaceuticals Alternatives Invivyd Alternatives Actuate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts